Core Viewpoint - The company has made a $5 million investment in the LFM Stable Income Fund SP, which is part of the LFM Oversea Investment Fund SPC, and is now pursuing legal action to recover this investment due to difficulties in redeeming it [1][2]. Group 1 - The company’s subsidiary, Biostar Pharma, Inc., subscribed to the LFM Stable Income Fund SP with $5 million using its idle funds, with the investment expected to mature on November 29, 2025 [1]. - The company submitted a redemption request on January 21, 2025, but has not received a timely response, prompting the decision to take legal action [2]. - Legal counsel has been appointed to advance the liquidation and takeover process of the LFM Fund under Cayman Islands law [2]. Group 2 - A petition was filed in the Cayman Islands Grand Court on September 12, 2025, seeking the appointment of a liquidator for the LFM Stable Income Fund SP [2]. - The court hearing regarding the takeover application took place on November 19, 2025, with a decision expected within two weeks [2]. - The company has issued a statutory demand to LFM Oversea Investment Limited, seeking joint liability for the redemption obligations under the subscription agreement [3].

本 公告 乃 由 北京 華 昊 中天 生 物 醫藥 股 份有 限 公 司（「本 公 司」）根據《香 港 聯合 交 易 所有 限 公 司證券上市規則（》「上市規則」）第13.09 (2)條及根據《證券及期貨條例》（ 香港法例第571章）第 XIVA部下的內幕信息條文（ 定義見上市規則）作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 內幕消息 截至本公告日期，本公司全資附屬公司Biostar Pharma, Inc.（「US -Biostar」）於2024年11月29日 使用其自有閒置資金認購LFM Oversea Investment Fund SPC（「該基金」）的獨立投資組合LFM Stable Income Fund SP（「子基 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 補充公告 截至2024年12月31日止年度之年報 茲提 述北 京華 昊中 天生 物醫 藥股 份有 限公 司（「 本公 司」）於2025 年7 月 24 日 刊發 之本 公司 截 至2024年12月31日止年度之年報（「2024年報」）。除另行界定外，本公告所用詞彙與2024年 報所載者具有相同涵義。 僱員激勵計劃 授出獎勵之詳情 截至2024年報日期，僱員激勵計劃授出獎勵之詳情如下： | | | | | | | | | | | 報告期內緊 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京華昊中天生物醫藥股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 216,720,857 | RMB | | | 1 RMB | | 216,720,857 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 216,720,857 | RMB | | | 1 RMB | | 216,720,857 | | 2. 股份分類 | ...

Summary of Key Points Group 1: 52-Week Highs - A total of 56 stocks reached their 52-week highs as of October 31, with New Silk Road Cultural Tourism (00472) leading with a high rate of 42.86% [1] - Other notable stocks include Dipu Technology (01384) at 25.07% and Tianren Group (01429) at 20.41% [1] - The table lists various stocks with their closing prices, highest prices, and the percentage increase from their previous highs [1] Group 2: 52-Week Lows - The report also highlights stocks that reached their 52-week lows, with Huahao Zhongtian Pharmaceutical - B (02563) showing a significant decline of 43.93% [2] - Other stocks with notable declines include Lion Holdings (02562) at -26.06% and Huili Resources (01303) at -15.00% [2] - The table provides details on the closing prices, lowest prices, and the percentage decrease for these stocks [2]

Market Overview - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in the Hong Kong stock market reached HKD 142.3 billion [1] Biotechnology Sector - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in several stocks: - InnoCare Pharma (09606) surged by 10.88% - 3SBio (01530) increased by over 10% - Innovent Biologics rose by 6.82% - Kelun-Biotech (06990) gained 5.69% [1] - Fosen Pharmaceuticals (01652) saw a significant increase, with a peak rise of nearly 74% and an early gain of 59.42% following the approval of Enzalutamide soft capsules and the potential selection of Metformin and Empagliflozin for national procurement [1] - Rongchang Biopharma (09995) rose by 6.75%, reporting a 40% year-on-year revenue growth and a significant reduction in losses for the first three quarters [1] Medical Sector - Spring Medical (01858) increased by over 21%, turning a profit of HKD 77.06 million in the third quarter as the company actively expands its international market [2] New Stocks Performance - Newly listed Dipo Technology (01384) continued to rise, gaining 18.97% and doubling its stock price within three days of listing [3] Financial Sector - China Everbright Bank (06818) fell by 5% post-earnings, with both revenue and profit declining in the third quarter, facing pressure from fair value changes [4] Other Notable Stocks - Huahao Zhongtian Pharmaceutical-B (02563) experienced a significant drop of over 37% due to a large unlock of shares after one year of listing [5] - Lion Holdings (02562) plummeted over 24% to a new low, planning to issue convertible bonds to raise approximately HKD 260 million for investments in gold and related products [6] - Air China (00753) dropped over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise up to HKD 20 billion through A-share placement [7]

智通财经APP获悉，华昊中天医药-B(02563)一度跌超37%，截至发稿，跌29.98%，报3.55港元，成交额 581.98万港元。 消息面上，华昊中天医药上市届满一年，今日迎来大额解禁，累计解禁股数约2.46亿股。今年上半年， 华昊中天医药实现营业收入1478.7万元(人民币，下同)，同比减少55.36%；净亏损5404.1万元，同比收 窄23.41%；基本每股亏损0.15元。 ...

每经AI快讯，华昊中天医药-B(02563.HK)一度跌超37%，截至发稿，跌29.98%，报3.55港元，成交额 581.98万港元。 ...

消息面上，华昊中天医药上市届满一年，今日迎来大额解禁，累计解禁股数约2.46亿股。今年上半年， 华昊中天医药实现营业收入1478.7万元(人民币，下同)，同比减少55.36%；净亏损5404.1万元，同比收 窄23.41%；基本每股亏损0.15元。 华昊中天医药-B(02563)一度跌超37%，截至发稿，跌29.98%，报3.55港元，成交额581.98万港元。 ...

Group 1 - The core viewpoint of the article highlights the recent stock deposit by shareholders of Huahao Zhongtian Pharmaceutical-B (02563) into Huatai Hong Kong, with a market value of HKD 125 million, representing 7.91% of the total shares [1] Group 2 - Huahao Zhongtian Pharmaceutical-B reported its interim results for the six months ending June 30, 2025, with a revenue of RMB 14.787 million, reflecting a year-on-year decrease of 55.36% [1] - The company experienced a net loss of RMB 54.041 million, which is a 23.41% reduction compared to the previous year [1] - The basic loss per share was reported at RMB 0.15 [1]